Ligand Pharmaceuticals (LGND) EPS (Weighted Average and Diluted) (2016 - 2025)
Historic EPS (Weighted Average and Diluted) for Ligand Pharmaceuticals (LGND) over the last 16 years, with Q3 2025 value amounting to $5.68.
- Ligand Pharmaceuticals' EPS (Weighted Average and Diluted) rose 155641.03% to $5.68 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.03, marking a year-over-year decrease of 1912.35%. This contributed to the annual value of -$0.22 for FY2024, which is 10727.55% down from last year.
- Ligand Pharmaceuticals' EPS (Weighted Average and Diluted) amounted to $5.68 in Q3 2025, which was up 155641.03% from $0.24 recorded in Q2 2025.
- In the past 5 years, Ligand Pharmaceuticals' EPS (Weighted Average and Diluted) registered a high of $5.68 during Q3 2025, and its lowest value of -$2.88 during Q2 2024.
- For the 5-year period, Ligand Pharmaceuticals' EPS (Weighted Average and Diluted) averaged around $0.59, with its median value being $0.24 (2025).
- As far as peak fluctuations go, Ligand Pharmaceuticals' EPS (Weighted Average and Diluted) crashed by 231538.46% in 2024, and later skyrocketed by 155641.03% in 2025.
- Quarter analysis of 5 years shows Ligand Pharmaceuticals' EPS (Weighted Average and Diluted) stood at -$0.13 in 2021, then crashed by 35.72% to -$0.17 in 2022, then surged by 688.75% to $1.03 in 2023, then tumbled by 265.02% to -$1.7 in 2024, then soared by 434.17% to $5.68 in 2025.
- Its last three reported values are $5.68 in Q3 2025, $0.24 for Q2 2025, and -$2.21 during Q1 2025.